Navigation Links
Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome
Date:4/17/2008

2, -1.9) (P=0.0003). In addition, a significantly greater proportion of patients treated with XP13512 (76.1 percent) was rated as responders on the CGI-I Scale compared to placebo (38.9 percent; P<0.0001).

Sleep disturbance is often associated with RLS. In this clinical trial, patients completed the Medical Outcomes Study (MOS) Sleep Scale to assess the impact of XP13512 treatment on sleep. At Week 12, XP13512-treated patients, compared to placebo-treated patients, had statistically significant improvements in sleep quantity and sleep adequacy, as well as statistically significant reductions in sleep disturbance and daytime somnolence.

The PIVOT RLS I clinical trial used a 24-hour diary to collect the presence and severity of RLS symptoms every 30 minutes starting at 8:00 a.m. At the end of the study, more than half of patients treated with XP13512 were symptom-free for the 24-hour assessment period compared to 18 percent of placebo-treated patients.

The two most commonly reported adverse events in the study were somnolence (27 percent, XP13512 vs. 7 percent, placebo) and dizziness (20 percent, XP13512 vs. 5 percent, placebo), with the majority reported as mild-to- moderate in intensity. Nine patients (8 percent) who received XP13512 withdrew from study participation due to adverse events compared to three patients (3 percent) who received placebo. No clinically meaningful changes in vital signs or laboratory parameters were observed.

In addition, the Epworth Sleepiness Scale (ESS), a reliable tool designed to measure daytime drowsiness, was used to evaluate the likelihood of patients dozing or falling asleep in common situations of daily living, such as sitting and reading or watching TV. At Week 12, the ESS scores for patients in the XP13512 group were lower than patients in the placebo group, indicating that XP13512 treatment was associated with less daytime drowsiness. The findings on the ESS scale are consistent with the reduction in
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
3. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
4. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
5. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
6. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Promising Data from Paratek Pharmaceuticals MAR Inhibitor Program Presented in Late Breaker Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
9. New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis
10. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... AMSTERDAM , July 25, 2014 ... America is returning for the seventh year to São ... to 7 th August 2014. The event will co-locate ... America,s most comprehensive meeting point for the pharmaceutical ... the top 25 countries for pharmaceutical sales are now exploring ...
(Date:7/24/2014)... 2014   AcelRx Pharmaceuticals, Inc.  (Nasdaq: ... development and commercialization of innovative therapies for the treatment ... date for Zalviso remains July 27, 2014.  ... stating the Food and Drug Administration (FDA) had approved ... no notification to the company from the FDA regarding ...
(Date:7/24/2014)... , Deutschland, und MARSEILLE ... , Weltweite Exklusivlizenz ... ermöglicht QIAGEN die Entwicklung von Tests auf ... Blutkrebs  Neuer Test weist Mutationen ... Knochenmarkserkrankungen (myelodysplastischen Syndromen) einen günstigen Krankheitsverlauf vermuten ...
Breaking Medicine Technology:CPhI South America 2014 Launches with Generics Showing Huge Growth 2CPhI South America 2014 Launches with Generics Showing Huge Growth 3CPhI South America 2014 Launches with Generics Showing Huge Growth 4AcelRx Pharmaceuticals Confirms July 27, 2014 PDUFA Date for Zalviso 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5
(Date:7/25/2014)... NY (PRWEB) July 25, 2014 ... prices across the board for the Guinness International Champions ... and Olympiacos FC at Soldier Field on Sunday, ... offering their customer appreciation promo/coupon/offer code SOCCER-2014 for added ... amazing year for diehard soccer fans in North America. ...
(Date:7/25/2014)... (HealthDay News) -- Seniors are more easily distracted during ... study finds. "Almost any type of memory test ... of 25 on," study co-author Randi Martin, professor of ... release. However, Martin said, this study shows that ... older adults compared with younger adults. The study ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 Sport ... for the recent Nike National Invitational Tournament (NIT) ... United States Junior National Tournament (USJN) in ... , The flooring for these prestigious national tournaments included ... 300,000 square feet of playing surface at McCormick Place ...
(Date:7/25/2014)... Reproductive Science Center (RSC) of New England ... Lead Physician at RSC Rhode Island, received the distinguished ... fertility care and community outreach issued by Providence Business ... Awards ceremony held July 24th at Salve Regina University ... regarded, emerging leaders in their field were recognized by ...
(Date:7/25/2014)... 25, 2014 Florida Hospital and MOSI officially ... organizations for years to come and make a difference in ... $2 million dollar check to provide the support needed to ... enable MOSI to transform the IMAX Dome Theatre from film ... the only IMAX Dome Theatre in the state of Florida, ...
Breaking Medicine News(10 mins):Health News:Liverpool FC vs. Olympiacos FC Tickets Soldier Field: Ticket Down Slashes Ticket Prices for Guinness International Champions Cup in Chicago on Sunday, July 27th 2Health News:Distractions Seem More Troublesome With Age 2Health News:Sport Court Provides All Sports Flooring for Basketball Events in Chicago and Washington D.C. 2Health News:Dr. Kerri Luzzo of the Reproductive Science Center of Providence Receives “40 Under Forty Award" for Outstanding Professional Accomplishments and Community Outreach 2Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 2Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 3Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 4
... may be associated with an increased ability to taste. For ... skip breakfast. The men had not eaten since 6:30 p.m. ... or bitter solutions and describe the flavor they tasted. The ... out after tasting them. One hour after lunch, the men ...
... with chemo-resistant leukemia, a new drug is showing promising ... experimenting with bacteria-based recombinant immunotoxins. An immunotoxin is bioengineered ... part of the antibodies that are commonly used to ... encouraging results in a phase II study. ,Researchers ...
... vaccine loses some of its effectiveness in the ... vaccinate their children against chickenpox between 12 months ... further investigate the vaccine after chickenpox outbreaks were ... nearly 350 children ages 13 months or older ...
... the third most common form of cancer in the United ... may provide protection against colon cancer. In addition, soy protein ... develop. ,Investigators fed five different diets to female mice ... designed to compare the effects of specific ingredients. Diet one ...
... up and get moving. Breast cancer survivors who ... esteem and better mood than sedentary breast cancer ... compared 40 women who said they regularly exercised ... survivors. Regular exercisers reported significantly more positive attitudes ...
... have an increased risk of heart disease and death. ... older women who participated in the Women's Health Initiative ... designed to determine how biological and lifestyle factors influence ... health conditions. For this study, participants were evaluated for ...
Cached Medicine News:
... holmium laser combines excellent cutting, ablation ... bloodless procedures. It is also extremely ... bladder stones of all compositions, making ... Because its laser light is transmitted ...
... new CO2 laser system with intensities up ... an exclusive design for easy handling and ... is the leader in a new generation ... of Dekas laser devices, like safety and ...
... The MedArt® 435 is a full system for ... which makes up a complete hair reduction system. ... ensure sufficient heating of the hair bulb and ... beam is distributed to the tissue through the ...
VERSASTEP™ Reposable Reusable Components (Standard Length)....
Medicine Products: